Glenn; Kevin C.

Patent Applications and Registrations

Patent applications and USPTO patent grants for Glenn; Kevin C..The latest application filed is for "combinations of cholesterol ester transfer protein inhibitors and hmg coa reductase inhibitors for cardiovascular indications".

Company Profile

0.12.17

Glenn; Kevin C. - Maryland Heights MO
Glenn, Kevin C - Maryland Heights MO
Glenn; Kevin C. - St. Louis MO

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
Combinations of Cholesterol Ester Transfer Protein Inhibitors and HMG COA Reductase Inhibitors for Cardiovascular Indications App 20070203246 - Keller; Bradley T. ; et al.	2007-08-30
Combination therapy employing ileal bile acid transport inhibiting benzothiepines and HMG CO-A reductase inhibitors Grant 6,943,189 - Keller , et al. September 13, 2	2005-09-13
Combinations of cholesteryl ester transfer protein inhibitors and nicotinic acid derivatives for cardiovascular indications Grant 6,890,958 - Sikorski , et al. May 10, 2	2005-05-10
Substituted pyridines useful for inhibiting cholesteryl ester transfer protein activity App 20040220231 - Lee, Len F. ; et al.	2004-11-04
Substituted pyridines useful for inhibiting cholesteryl ester transfer protein activity Grant 6,794,396 - Lee , et al. September 21, 2	2004-09-21
Combination therapy employing ileal bile acid transport inhibiting benzothiepines and HMG Co-A reductase inhibitors App 20040157915 - Keller, Bradley T. ; et al.	2004-08-12
Combination therapy for the prophylaxis and treatment of hyperlipidemic conditions and disorders App 20040110761 - Keller, Bradley T. ; et al.	2004-06-10
Combinations of ileal bile acid transport inhibitors and fibric acid derivatives for cardiovascular indications App 20040048846 - Keller, Bradley T. ; et al.	2004-03-11
Substituted pyridines useful for inhibiting cholesteryl ester transfer protein activity App 20040038939 - Lee, Len F. ; et al.	2004-02-26
Combinations of cholesteryl ester transfer protein inhibitors and bile acid sequestering agents for cardiovascular indications App 20040028644 - Sikorski, James A. ; et al.	2004-02-12
Combinations of ileal bile acid transport inhibitors and bile acid sequestering agents for cardiovascular indications App 20040029845 - Keller, Bradley T. ; et al.	2004-02-12
Combination therapy for the prophylaxis and treatment of hyperlipidemic conditions and disorders App 20030232834 - Keller, Bradley T ; et al.	2003-12-18
Combination therapy employing ileal bile acid transport inhibiting benzothipines and HMG Co-A reductase inhibitors Grant 6,642,268 - Keller , et al. November 4, 2	2003-11-04
Combinations of ileal bile acid transport inhibitors and cholesteryl ester transfer protein inhibitors for cardiovascular indications App 20030203892 - Keller, Bradley T. ; et al.	2003-10-30
Combinations of ileal bile acid transport inhibitors and fibric acid derivatives for cardiovascular indications Grant 6,638,969 - Keller , et al. October 28, 2	2003-10-28
Thrombin derived polypeptides: compositions and methods for use Grant 6,630,572 - Carney , et al. October 7, 2	2003-10-07
Thrombin derived polypeptides; compositions and methods for use Grant 6,627,731 - Carney , et al. September 30, 2	2003-09-30
Combination therapy employing ileal bile acid transport inhibiting benzothiepiens and HMG Co-A reductase inhibitors App 20030171426 - Keller, Bradley T. ; et al.	2003-09-11
Combinations of cholesteryl ester transfer protein inhibitors and fibric acid derivatives for cardiovascular indications App 20030166720 - Sikorski, James A. ; et al.	2003-09-04
Combinations of cholesteryl ester transfer protein inhibitors and HMG CoA reductase inhibitors for cardiovascular indications App 20030166712 - Keller, Bradley T. ; et al.	2003-09-04
Substituted pyridines useful for inhibiting cholesteryl ester transfer protein activity Grant 6,605,624 - Lee , et al. August 12, 2	2003-08-12
Combinations of lleal bile acid transport inhibitors and nicotinic acid derivatives for cardiovascular indications App 20030125316 - Keller, Bradley T. ; et al.	2003-07-03
Restoration of platelet aggregation by antibody administration after GPIIB/IIIa antagonist treatment App 20030118584 - Glenn, Kevin C. ; et al.	2003-06-26
Combinations of cholesteryl ester transfer protein inhibitors and nicotinic acid derivatives for cardiovascular indications App 20030109558 - Sikorski, James A. ; et al.	2003-06-12
Combinations of ileal bile acid transport inhibitors and cholesteryl ester transfer protein inhibitors for cardiovascular indications Grant 6,458,851 - Keller , et al. October 1, 2	2002-10-01
Combination therapy employing ileal bile acid transport inhibiting benzothiepines and HMG Co-A reductase inhibitors Grant 6,420,417 - Keller , et al. July 16, 2	2002-07-16
Combination therapy for the prophylaxis and treatment of hyperlipidemic conditions and disorders App 20020061888 - Keller, Bradley T. ; et al.	2002-05-23
Thrombin derived polypeptides; compositions and methods for use Grant 5,500,412 - Carney , et al. March 19, 1	1996-03-19
Thrombin derived polypeptides; compositions and methods for use Grant 5,352,664 - Carney , et al. October 4, 1	1994-10-04

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.